Compass (COMP) Company Report

Compass Therapeutics expects progression-free survival and overall survival analyses for its Phase 2/3 COMPANION-002 study of tovecimig in advanced biliary tract cancer to remain on track for late Q1 2026.
The company's CTX-8371 PD-1 x PD-L1 bispecific antibody has demonstrated responses in patients with solid tumor and hematologic malignancies, with cohort expansions now open for enrollment in triple-negative breast cancer and NSCLC.
Compass expanded its senior leadership team with the appointments of Arjun Prasad as Chief Commercial Officer and Cynthia Sirard, M.D., as Chief Medical Officer.
As of December 31, 2025, Compass Therapeutics estimated $209 million in cash and marketable securities, which is expected to provide a cash runway into 2028.

6 days ago

Press Release

Compass completes all-stock combination with Anywhere Real Estate Inc.

COMP

M&A

New Projects/Investments

Compass, Inc. (NYSE: COMP) has completed its all-stock combination with Anywhere Real Estate Inc..
The combined companies will operate under Compass International Holdings, led by Robert Reffkin as Chairman and CEO.
The merger aims to empower real estate professionals with a single, modern technology platform, building on Compass's position as the largest residential real estate brokerage in the United States by sales volume.

Jan 9, 2026, 1:00 PM

Press Release

Compass Announces Pricing of Convertible Senior Notes

COMP

Debt Issuance

M&A

Compass, Inc. announced the pricing of $850.0 million in aggregate principal amount of convertible senior notes due 2031 in a private offering, representing a $100.0 million increase from the previously announced size.
The net proceeds from the offering are intended for general corporate purposes, including the repayment of certain existing indebtedness of Anywhere Real Estate Inc. if the merger is completed, and funding the net cost of capped call transactions.
The notes will bear interest at 0.25% per annum and mature on April 15, 2031. The initial conversion price is approximately $15.98 per share of Class A common stock, which is a 35.0% conversion premium over the January 7, 2026 sale price.
In connection with the notes, Compass entered into capped call transactions with an initial cap price of $23.68 per share, representing a 100.0% premium over the last reported sale price of its Class A common stock on January 7, 2026.

Jan 8, 2026, 11:15 AM

Press Release

Compass and Anywhere Stockholders Approve Merger

COMP

M&A

Proxy Vote Outcomes

Stockholders of Compass, Inc. and Anywhere Real Estate Inc. have overwhelmingly approved all proposals related to their previously announced merger.
The merger is expected to close on January 9, 2026, pending the satisfaction of customary closing conditions.
Approximately 99% of the votes cast at Compass' special stockholders meeting approved the proposal to issue shares of Compass Class A common stock to Anywhere stockholders.
Approximately 72.4% of the outstanding shares of Anywhere's common stock voted to approve the merger agreement.

Jan 7, 2026, 8:37 PM

Press Release

Compass, Inc. Announces Proposed Convertible Senior Notes Offering and Q4 2025 Guidance Update

COMP

Debt Issuance

Guidance Update

M&A

Compass, Inc. announced a proposed private offering of $750.0 million in aggregate principal amount of convertible senior notes due 2031.
The company also intends to grant initial purchasers an option to purchase up to an additional $112.5 million aggregate principal amount of these notes.
Net proceeds from the offering are intended for general corporate purposes, including the repayment of certain existing indebtedness of Anywhere Real Estate Inc. if their merger is completed, and funding capped call transactions.
For the fourth quarter of 2025, Compass updated its financial guidance, expecting revenue to be at the high end of the previously announced range of $1.59 billion to $1.69 billion and Adjusted EBITDA to be at or slightly above the high end of $35 million to $49 million.
Additionally, Compass added over 800 principal agents during the fourth quarter of 2025.

Jan 7, 2026, 12:05 PM

8-K

Compass Announces Proposed Offering of Convertible Senior Notes

COMP

Debt Issuance

Convertible Preferred Issuance

M&A

Compass, Inc. (NYSE: COMP) intends to offer $750.0 million in aggregate principal amount of convertible senior notes due 2031 in a private offering, with an option for initial purchasers to buy an additional $112.5 million.
The net proceeds from the offering are intended for general corporate purposes, including the repayment of certain existing indebtedness of Anywhere Real Estate Inc. if the merger is completed, and funding the net cost of capped call transactions.
The notes will be senior unsecured obligations, and the company expects to enter into capped call transactions to generally reduce potential dilution to its Class A common stock upon conversion.

Jan 7, 2026, 12:05 PM

Press Release

Compass Releases 2026 Housing Market Outlook

COMP

Guidance Update

Compass's 2026 Housing Market Outlook predicts a recalibrated market with improved affordability and stronger sales after a period of slow home sales and high prices.
Key projections for 2026 include national home price growth of +0.5%, a 5% increase in inventory, average mortgage rates around 6.4%, and existing home sales increasing by 4.25% to 5% from 2025.
The outlook highlights improved affordability as wages are expected to grow faster than home prices, a return to American mobility, and diverging economic and geographic conditions, with the luxury segment expected to continue thriving.

Dec 11, 2025, 9:00 PM

Press Release

Compass, Inc. Enters into Revolving Credit and Guaranty Agreement

COMP

Debt Issuance

M&A

Compass, Inc. executed a Revolving Credit and Guaranty Agreement dated November 17, 2025, with Morgan Stanley Senior Funding, Inc. as the Administrative Agent and Collateral Agent, and other lenders.
This agreement is associated with the Aspen Acquisition, which involves Compass, Inc.'s acquisition of Aspen and its subsidiaries, and many financial covenants and debt limits are modified on and after the Aspen Acquisition Effective Date.
Prior to the Aspen Acquisition Effective Date, Compass, Inc. is required to maintain minimum liquidity of $150,000,000 and consolidated total revenue of at least $4,000,000,000 for the trailing four fiscal quarters.
The maximum Total Net Leverage Ratio covenant will increase from 3.00:1.00 before the Aspen Acquisition Effective Date to 5.00:1.00 on or prior to September 30, 2027, then decrease to 4.50:1.00 by December 31, 2027, and 4.25:1.00 by December 31, 2028.
Post-Aspen Acquisition, the company's debt capacity expands, allowing for up to $750,000,000 under a Bridge Credit Agreement/Replacement Facility and up to $1,140,000,000 for Aspen Second Lien Notes.

Nov 17, 2025, 10:15 PM

8-K

Compass Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Update

COMP

Earnings

Guidance Update

New Projects/Investments

Compass Therapeutics reported a net loss of $14.3 million or $0.08 per share for the third quarter ended September 30, 2025.
As of September 30, 2025, the company held $220 million in cash and marketable securities, which is expected to provide a cash runway into 2028.
Key pipeline updates include expected overall survival and progression-free survival analyses for tovecimig in late Q1 2026 , planned cohort expansions for CTX-8371 in Q4 2025 , and an IND filing for CTX-10726 in Q4 2025.

Nov 5, 2025, 12:30 PM

Press Release

LTC Properties Reports Q3 2025 Results and Raises Guidance

COMP

Earnings

Guidance Update

New Projects/Investments

LTC Properties reported its 2025 third quarter results and increased its full-year 2025 guidance for the third time, driven by acquisitions and SHOP outperformance.
The company's SHOP portfolio grew to nearly $450 million by September 30, 2025, representing approximately 20% of its total investment portfolio with an average occupancy of 87%.
LTC expects to close an additional $70 million in SHOP acquisitions by year-end 2025 and $110 million in January 2026.
For the third quarter ended September 30, 2025, Diluted Core FFO per share was $0.69 and Diluted Core FAD per share was $0.72. The updated full-year 2025 guidance for Diluted Core FFO is $2.69 to $2.71 per share and for Diluted Core FAD is $2.82 to $2.84 per share.